Citicoline Treatment in Acute Ischemic Stroke: A Randomized, Single-Blind TMS Study
BackgroundRecent research on animal models of ischemic stroke supports the idea that pharmacological treatment potentially enhancing intrinsic brain plasticity could modulate acute brain damage, with improved functional recovery. One of these new drugs is citicoline, which could provide neurovascula...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2022.915362/full |
| _version_ | 1811294313768812544 |
|---|---|
| author | Enrico Premi Valentina Cantoni Valentina Cantoni Alberto Benussi Alberto Benussi Nicola Gilberti Veronica Vergani Ilenia Delrio Massimo Gamba Raffaella Spezi Angelo Costa Alessandro Padovani Alessandro Padovani Barbara Borroni Barbara Borroni Mauro Magoni |
| author_facet | Enrico Premi Valentina Cantoni Valentina Cantoni Alberto Benussi Alberto Benussi Nicola Gilberti Veronica Vergani Ilenia Delrio Massimo Gamba Raffaella Spezi Angelo Costa Alessandro Padovani Alessandro Padovani Barbara Borroni Barbara Borroni Mauro Magoni |
| author_sort | Enrico Premi |
| collection | DOAJ |
| description | BackgroundRecent research on animal models of ischemic stroke supports the idea that pharmacological treatment potentially enhancing intrinsic brain plasticity could modulate acute brain damage, with improved functional recovery. One of these new drugs is citicoline, which could provide neurovascular protection and repair effects.ObjectivesThe objective of this randomized, single-blind experimental study was to evaluate whether the treatment with Rischiaril® Forte was able to restore intracortical excitability measures, evaluated through transcranial magnetic stimulation (TMS) protocols, in patients with acute ischemic stroke.MethodsPatients with acute ischemic stroke were recruited and assigned to an eight-week therapy of standard treatment (control group - CG) or CDP-choline (Rischiaril® Forte, containing 1,000 mg of citicoline sodium salt) added to conventional treatment (treatment group - TG). Each subject underwent a clinical evaluation and neurophysiological assessment using TMS, pretretament and posttreatment.ResultsA total of thirty participants (mean [SD] age, 68.1 [9.6] years; 11 women [37%]) completed the study. We did not observe significant changes in clinical scores after CDP-choline treatment (all p > 0.05), but we observed a significant improvement in short-interval intracortical inhibition (SAI) (p = 0.003) in the TG group compared to the CG group.ConclusionsThe eight-week treatment with citicoline after acute ischemic stroke may restore intracortical excitability measures, which partially depends on cholinergic transmission. This study extends current knowledge of the application of citicoline in acute ischemic stroke. |
| first_indexed | 2024-04-13T05:14:38Z |
| format | Article |
| id | doaj.art-6671c9b953f74fbfab25fe08f35b9058 |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-04-13T05:14:38Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-6671c9b953f74fbfab25fe08f35b90582022-12-22T03:00:55ZengFrontiers Media S.A.Frontiers in Neurology1664-22952022-07-011310.3389/fneur.2022.915362915362Citicoline Treatment in Acute Ischemic Stroke: A Randomized, Single-Blind TMS StudyEnrico Premi0Valentina Cantoni1Valentina Cantoni2Alberto Benussi3Alberto Benussi4Nicola Gilberti5Veronica Vergani6Ilenia Delrio7Massimo Gamba8Raffaella Spezi9Angelo Costa10Alessandro Padovani11Alessandro Padovani12Barbara Borroni13Barbara Borroni14Mauro Magoni15Stroke Unit, Azienda Socio Sanitaria Territoriale Spedali Civili, Brescia, ItalyNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, ItalyDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, ItalyNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, ItalyNeurology Unit, Department of Neurological and Vision Sciences, ASST Spedali Civili, Brescia, ItalyStroke Unit, Azienda Socio Sanitaria Territoriale Spedali Civili, Brescia, ItalyStroke Unit, Azienda Socio Sanitaria Territoriale Spedali Civili, Brescia, ItalyStroke Unit, Azienda Socio Sanitaria Territoriale Spedali Civili, Brescia, ItalyStroke Unit, Azienda Socio Sanitaria Territoriale Spedali Civili, Brescia, ItalyStroke Unit, Azienda Socio Sanitaria Territoriale Spedali Civili, Brescia, ItalyStroke Unit, Azienda Socio Sanitaria Territoriale Spedali Civili, Brescia, ItalyNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, ItalyNeurology Unit, Department of Neurological and Vision Sciences, ASST Spedali Civili, Brescia, ItalyNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, ItalyNeurology Unit, Department of Neurological and Vision Sciences, ASST Spedali Civili, Brescia, ItalyStroke Unit, Azienda Socio Sanitaria Territoriale Spedali Civili, Brescia, ItalyBackgroundRecent research on animal models of ischemic stroke supports the idea that pharmacological treatment potentially enhancing intrinsic brain plasticity could modulate acute brain damage, with improved functional recovery. One of these new drugs is citicoline, which could provide neurovascular protection and repair effects.ObjectivesThe objective of this randomized, single-blind experimental study was to evaluate whether the treatment with Rischiaril® Forte was able to restore intracortical excitability measures, evaluated through transcranial magnetic stimulation (TMS) protocols, in patients with acute ischemic stroke.MethodsPatients with acute ischemic stroke were recruited and assigned to an eight-week therapy of standard treatment (control group - CG) or CDP-choline (Rischiaril® Forte, containing 1,000 mg of citicoline sodium salt) added to conventional treatment (treatment group - TG). Each subject underwent a clinical evaluation and neurophysiological assessment using TMS, pretretament and posttreatment.ResultsA total of thirty participants (mean [SD] age, 68.1 [9.6] years; 11 women [37%]) completed the study. We did not observe significant changes in clinical scores after CDP-choline treatment (all p > 0.05), but we observed a significant improvement in short-interval intracortical inhibition (SAI) (p = 0.003) in the TG group compared to the CG group.ConclusionsThe eight-week treatment with citicoline after acute ischemic stroke may restore intracortical excitability measures, which partially depends on cholinergic transmission. This study extends current knowledge of the application of citicoline in acute ischemic stroke.https://www.frontiersin.org/articles/10.3389/fneur.2022.915362/fullstroketranscranial magnetic stimulationshort-latency afferent inhibition (SAI)citicolinecholinergic system (CS) |
| spellingShingle | Enrico Premi Valentina Cantoni Valentina Cantoni Alberto Benussi Alberto Benussi Nicola Gilberti Veronica Vergani Ilenia Delrio Massimo Gamba Raffaella Spezi Angelo Costa Alessandro Padovani Alessandro Padovani Barbara Borroni Barbara Borroni Mauro Magoni Citicoline Treatment in Acute Ischemic Stroke: A Randomized, Single-Blind TMS Study Frontiers in Neurology stroke transcranial magnetic stimulation short-latency afferent inhibition (SAI) citicoline cholinergic system (CS) |
| title | Citicoline Treatment in Acute Ischemic Stroke: A Randomized, Single-Blind TMS Study |
| title_full | Citicoline Treatment in Acute Ischemic Stroke: A Randomized, Single-Blind TMS Study |
| title_fullStr | Citicoline Treatment in Acute Ischemic Stroke: A Randomized, Single-Blind TMS Study |
| title_full_unstemmed | Citicoline Treatment in Acute Ischemic Stroke: A Randomized, Single-Blind TMS Study |
| title_short | Citicoline Treatment in Acute Ischemic Stroke: A Randomized, Single-Blind TMS Study |
| title_sort | citicoline treatment in acute ischemic stroke a randomized single blind tms study |
| topic | stroke transcranial magnetic stimulation short-latency afferent inhibition (SAI) citicoline cholinergic system (CS) |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2022.915362/full |
| work_keys_str_mv | AT enricopremi citicolinetreatmentinacuteischemicstrokearandomizedsingleblindtmsstudy AT valentinacantoni citicolinetreatmentinacuteischemicstrokearandomizedsingleblindtmsstudy AT valentinacantoni citicolinetreatmentinacuteischemicstrokearandomizedsingleblindtmsstudy AT albertobenussi citicolinetreatmentinacuteischemicstrokearandomizedsingleblindtmsstudy AT albertobenussi citicolinetreatmentinacuteischemicstrokearandomizedsingleblindtmsstudy AT nicolagilberti citicolinetreatmentinacuteischemicstrokearandomizedsingleblindtmsstudy AT veronicavergani citicolinetreatmentinacuteischemicstrokearandomizedsingleblindtmsstudy AT ileniadelrio citicolinetreatmentinacuteischemicstrokearandomizedsingleblindtmsstudy AT massimogamba citicolinetreatmentinacuteischemicstrokearandomizedsingleblindtmsstudy AT raffaellaspezi citicolinetreatmentinacuteischemicstrokearandomizedsingleblindtmsstudy AT angelocosta citicolinetreatmentinacuteischemicstrokearandomizedsingleblindtmsstudy AT alessandropadovani citicolinetreatmentinacuteischemicstrokearandomizedsingleblindtmsstudy AT alessandropadovani citicolinetreatmentinacuteischemicstrokearandomizedsingleblindtmsstudy AT barbaraborroni citicolinetreatmentinacuteischemicstrokearandomizedsingleblindtmsstudy AT barbaraborroni citicolinetreatmentinacuteischemicstrokearandomizedsingleblindtmsstudy AT mauromagoni citicolinetreatmentinacuteischemicstrokearandomizedsingleblindtmsstudy |